I 

117TH CONGRESS 

1ST SESSION H. R. 1371 

Making supplemental appropriations for the fiscal year ending September 

30, 2021, providing coronavirus emergency response and relief, and for 

other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 25, 2021 

Mr. REED introduced the following bill; which was referred to the Committee 

on Appropriations, and in addition to the Committee on the Budget, for 

a period to be subsequently determined by the Speaker, in each case for 

consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

Making supplemental appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Crush the Virus Act 

5 of 2021’’. 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•HR 1371 IH

1 SEC. 2. FUNDING FOR COVID–19 VACCINE ACTIVITIES AT 

2 THE CENTERS FOR DISEASE CONTROL AND 

3 PREVENTION. 

4 (a) IN GENERAL.—In addition to amounts otherwise 

5 available, there is appropriated to the Secretary of Health 

6 and Human Services (in this Act referred to as the ‘‘Sec7 retary’’) for fiscal year 2021, out of any money in the 

8 Treasury not otherwise appropriated, $8,500,000,000, to 

9 remain available until expended, to carry out activities to 

10 plan, prepare for, promote, distribute, administer, mon11 itor, and track COVID–19 vaccines, working with States, 

12 territories, and Tribes. 

13 (b) USE OF FUNDS.—The Secretary, acting through 

14 the Director of the Centers for Disease Control and Pre15 vention, and in consultation with other agencies, as appli16 cable, shall, in conducting activities referred to in sub17 section (a)— 

18 (1) enhance, expand, and improve nationwide 

19 COVID–19 vaccine distribution and administration, 

20 including activities related to distribution of ancil21 lary medical products and supplies related to vac22 cines; 

23 (2) provide for the vaccination of employees and 

24 individuals working or residing in congregate set25 tings and other high-risk environments; 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•HR 1371 IH

1 (3) provide information and public outreach, 

2 that is culturally and linguistically appropriate, with 

3 respect to vaccines licensed under section 351 of the 

4 Public Health Service Act (42 U.S.C. 262) or au5 thorized under section 564 of the Federal Food, 

6 Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) in 

7 order to strengthen vaccine confidence in the United 

8 States, including its territories and possessions, par9 ticularly in minority and underserved communities 

10 with low rates of vaccination; and 

11 (4) provide technical assistance, guidance, and 

12 support to, and award grants or cooperative agree13 ments to, State, local, Tribal, and territorial public 

14 health departments for enhancement of COVID–19 

15 vaccine distribution and administration capabilities, 

16 including— 

17 (A) the distribution and administration of 

18 vaccines licensed under section 351 of the Pub19 lic Health Service Act (42 U.S.C. 262) or au20 thorized under section 564 of the Federal Food, 

21 Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) 

22 and ancillary medical products and supplies re23 lated to vaccines; 

24 (B) the establishment and expansion, in25 cluding staffing support, of community vaccinaVerDate Sep 11 2014 21:09 Feb 26, 2021 Jkt 019200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1371.IH H1371

pamtmann on DSKBC07HB2PROD with BILLS
4 

•HR 1371 IH

1 tion centers, particularly in rural, frontier, and 

2 underserved areas; 

3 (C) the deployment of mobile vaccination 

4 units, particularly in rural, frontier, and under5 served areas; 

6 (D) information technology, data, and re7 porting enhancements, including improvements 

8 necessary to support sharing of data related to 

9 vaccine distribution and vaccinations and sys10 tems that enhance vaccine safety, effectiveness, 

11 and uptake, particularly among underserved 

12 populations; 

13 (E) facilities enhancements; and 

14 (F) communication with the public regard15 ing when, where, and how to receive COVID– 

16 19 vaccines. 

17 SEC. 3. FUNDING RESEARCH ON AND DEVELOPMENT OF 

18 COVID–19 VACCINES, THERAPEUTICS, AND 

19 MEDICAL SUPPLIES. 

20 In addition to amounts otherwise available, there is 

21 appropriated to the Public Health and Social Services 

22 Emergency Fund for fiscal year 2021, out of any money 

23 in the Treasury not otherwise appropriated, 

24 $11,500,000,000, to remain available until expended, for 

25 necessary expenses with respect to research, development, 


pamtmann on DSKBC07HB2PROD with BILLS
5 

•HR 1371 IH

1 manufacturing, production, and the purchase of vaccines, 

2 therapeutics, and ancillary medical products and supplies 

3 to prevent, prepare, or respond to— 

4 (1) SARS–CoV–2 or any viral variant mutating 

5 therefrom with pandemic potential; and 

6 (2) COVID–19 or any disease with potential for 

7 creating a pandemic. 

8 SEC. 4. FUNDING FOR COVID–19 TESTING, CONTACT TRAC9 ING, AND MITIGATION ACTIVITIES. 

10 (a) IN GENERAL.—In addition to amounts otherwise 

11 available, there is appropriated to the Secretary for fiscal 

12 year 2021, out of any money in the Treasury not otherwise 

13 appropriated, $50,000,000,000, to remain available until 

14 expended, to carry out activities to detect, diagnose, trace, 

15 and monitor SARS–CoV–2 and COVID–19 infections and 

16 related strategies to mitigate the spread of COVID–19, 

17 working with States, territories, and Tribes. 

18 (b) USE OF FUNDS.—From amounts appropriated by 

19 subsection (a), the Secretary shall— 

20 (1) implement an evidence-based strategy for 

21 testing, contact tracing, surveillance, and mitigation 

22 with respect to SARS–CoV–2 and COVID–19; 

23 (2) provide technical assistance, guidance, and 

24 support, and award grants or cooperative agree25 ments to State, local, and territorial public health 


pamtmann on DSKBC07HB2PROD with BILLS
6 

•HR 1371 IH

1 departments for activities to detect, diagnose, trace, 

2 and monitor SARS–CoV–2 and COVID–19 infec3 tions and related strategies and activities to mitigate 

4 the spread of COVID–19; 

5 (3) award grants or cooperative agreements to 

6 State, local, Tribal, or territorial public health de7 partments or public health laboratories— 

8 (A) to increase their capacity to sequence 

9 genomes of circulating strains of viruses and 

10 other organisms, including SARS–CoV–2; 

11 (B) to identify mutations in viruses and 

12 other organisms, including SARS–CoV–2; 

13 (C) to use genomic sequencing to identify 

14 outbreaks and clusters of diseases or infections, 

15 including COVID–19; and 

16 (D) to develop effective disease response 

17 strategies based on genomic sequencing and 

18 surveillance data; 

19 (4) support the development, manufacturing, 

20 procurement, distribution, and administration of 

21 tests to detect or diagnose SARS–CoV–2 and 

22 COVID–19, including supplies necessary for admin23 istering tests, such as personal protective equipment; 

24 (5) establish and expand Federal, State, local, 

25 and territorial testing and contact tracing capabiliVerDate Sep 11 2014 21:09 Feb 26, 2021 Jkt 019200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H1371.IH H1371

pamtmann on DSKBC07HB2PROD with BILLS
7 

•HR 1371 IH

1 ties, including investments in laboratory capacity, 

2 community-based testing sites, and mobile testing 

3 units, particularly in rural, frontier, and medically 

4 underserved areas; 

5 (6) enhance information technology, data mod6 ernization, and reporting, including improvements 

7 necessary to support sharing of data related to pub8 lic health capabilities; 

9 (7) award grants to, or enter into cooperative 

10 agreements or contracts with, State, local, and terri11 torial public health departments to establish, ex12 pand, and sustain a public health workforce; and 

13 (8) to cover administrative and program sup14 port costs necessary to conduct activities related to 

15 subparagraph (a). 

16 SEC. 5. FEDERAL EMERGENCY MANAGEMENT AGENCY AP17 PROPRIATION. 

18 In addition to amounts otherwise available, there is 

19 appropriated to the Federal Emergency Management 

20 Agency for fiscal year 2021, out of any money in the 

21 Treasury not otherwise appropriated, $30,000,000,000, to 

22 remain available until September 30, 2025, for major dis23 asters declared pursuant to the Robert T. Stafford Dis24 aster Relief and Emergency Assistance Act (42 U.S.C. 

25 5121 et seq.). 


pamtmann on DSKBC07HB2PROD with BILLS
8 

•HR 1371 IH

1 SEC. 6. COVID–19 EMERGENCY MEDICAL SUPPLIES EN2 HANCEMENT. 

3 (a) SUPPORTING ENHANCED USE OF THE DEFENSE

4 PRODUCTION ACT OF 1950.—In addition to funds other5 wise available, there is appropriated, for fiscal year 2021, 

6 out of any money in the Treasury not otherwise appro7 priated, $5,000,000,000, to remain available until Sep8 tember 30, 2025, to carry out titles I, III, and VII of the 

9 Defense Production Act of 1950 (50 U.S.C. 4501 et seq.) 

10 in accordance with subsection (b). 

11 (b) MEDICAL SUPPLIES AND EQUIPMENT.—Amounts 

12 appropriated in subsection (a) shall be used for the pur13 chase, production (including the construction, repair, and 

14 retrofitting of government-owned or private facilities as 

15 necessary), or distribution of medical supplies and equip16 ment (including durable medical equipment) related to 

17 combating the COVID–19 pandemic, including— 

18 (1) in vitro diagnostic products (as defined in 

19 section 809.3(a) of title 21, Code of Federal Regula20 tions) for the detection of SARS–CoV–2 or the diag21 nosis of the virus that causes COVID–19, and the 

22 reagents and other materials necessary for pro23 ducing, conducting, or administering such products, 

24 and the machinery, equipment, laboratory capacity, 

25 or other technology necessary to produce such prod26 ucts; 


pamtmann on DSKBC07HB2PROD with BILLS
9 

•HR 1371 IH

1 (2) face masks and personal protective equip2 ment, including face shields, nitrile gloves, N–95 fil3 tering facepiece respirators, and any other masks or 

4 equipment (including durable medical equipment) 

5 determined by the Secretary of Health and Human 

6 Services to be needed to respond to the COVID–19 

7 pandemic, and the materials, machinery, additional 

8 manufacturing lines or facilities, or other technology 

9 necessary to produce such equipment; and 

10 (3) drugs and devices (as those terms are de11 fined in the Federal Food, Drug, and Cosmetic Act 

12 (21 U.S.C. 301 et seq.)) and biological products (as 

13 that term is defined by section 351 of the Public 

14 Health Service Act (42 U.S.C. 262)) that are ap15 proved, cleared, licensed, or authorized under either 

16 of such Acts for use in treating or preventing 

17 COVID–19 and symptoms related to COVID–19, 

18 and any materials, manufacturing machinery, addi19 tional manufacturing or fill-finish lines or facilities, 

20 technology, or equipment (including durable medical 

21 equipment) necessary to produce or use such drugs, 

22 biological products, or devices (including syringes, 

23 vials, or other supplies or equipment related to deliv24 ery, distribution, or administration). 


pamtmann on DSKBC07HB2PROD with BILLS
10 

•HR 1371 IH

1 (c) DELEGATION AUTHORITY.—For purposes of 

2 using amounts appropriated in subsection (a), the Presi3 dent shall only delegate authority to, with respect to any 

4 uses described under subsection (b)— 

5 (1) the Secretary of Health and Human Serv6 ices; and 

7 (2) the head of any other agency responsible for 

8 responding to the COVID–19 pandemic if the Presi9 dent determines that such delegation is important to 

10 an effective response to such pandemic. 

11 (d) APPLICATION OF LIMITATIONS UNDER THE DE12 FENSE PRODUCTION ACT OF 1950.—The requirements 

13 described in section 304(e) of the Defense Production Act 

14 of 1950 (50 U.S.C. 4534(e)) shall not apply to the funds 

15 appropriated in subsection (a) until September 30, 2025. 

16 SEC. 7. PERSONAL PROTECTIVE EQUIPMENT. 

17 In addition to amounts otherwise available, there is 

18 appropriated to the Secretary for fiscal year 2021, out of 

19 any money in the Treasury not otherwise appropriated, 

20 $5,000,000,000 to remain available until expended, for 

21 necessary expenses with respect to the manufacturing, ac22 quisition, and distribution of personal protective equip23 ment for preventing the spread of COVID–19. 


pamtmann on DSKBC07HB2PROD with BILLS
11 

•HR 1371 IH

1 SEC. 8. STRATEGIC NATIONAL STOCKPILE. 

2 In addition to amounts otherwise available, there is 

3 appropriated to the Secretary for fiscal year 2021, out of 

4 any money in the Treasury not otherwise appropriated, 

5 $15,000,000,000, to remain available until expended, for 

6 necessary expenses with respect to the procurement and 

7 stockpile pursuant to section 319F–2 of the Public Health 

8 Service Act (42 U.S.C. 247d–6b) of vaccines, therapeutics, 

9 and ancillary medical products and supplies to prevent, 

10 prepare, or respond to SARS–CoV–2 or any viral variant 

11 mutating therefrom with pandemic potential, and 

12 COVID–19. 

13 SEC. 9. PROVIDER RELIEF FUND. 

14 (a) In addition to amounts otherwise available, there 

15 is appropriated for the Public Health and Social Services 

16 Emergency Fund for fiscal year 2021, out of any money 

17 in the Treasury not otherwise appropriated, 

18 $35,000,000,000, to remain available until expended, to 

19 prevent, prepare for, and respond to COVID–19, domesti20 cally or internationally, for necessary expenses to reim21 burse, through grants or other mechanisms, eligible health 

22 care providers for health care related expenses or lost reve23 nues that are attributable to coronavirus. 

24 (b) Of the eligible health care providers that are re25 cipients of payments under this section, $7,000,000,000 

26 of such amount shall be for suppliers and providers located 


pamtmann on DSKBC07HB2PROD with BILLS
12 

•HR 1371 IH

1 in a rural area (as defined in section 1886(d)(2)(D) of 

2 the Social Security Act (42 U.S.C. 1395ww(d)(2)(D))). 

3 (c) These funds may not be used to reimburse ex4 penses or losses that have been reimbursed from other 

5 sources or that other sources are obligated to reimburse. 

6 (d) Recipients of payments under this section shall 

7 submit reports and maintain documentation as the Sec8 retary determines are needed to ensure compliance with 

9 conditions that are imposed by this section for such pay10 ments, and such reports and documentation shall be in 

11 such form, with such content, and in such time as the Sec12 retary may prescribe for such purpose. 

13 (e) The term ‘‘eligible health care providers’’ means 

14 public entities, Medicare or Medicaid enrolled suppliers 

15 and providers, and such for-profit entities and not-for16 profit entities not otherwise described in this subsection 

17 as the Secretary may specify, within the United States (in18 cluding territories), that provide diagnoses, testing, or 

19 care for individuals with possible or actual cases of 

20 COVID–19. 

21 (f) The Secretary of Health and Human Services 

22 shall, on a rolling basis, review applications and make pay23 ments under this section in this Act. 

24 (g) Funds appropriated under this section in this Act 

25 shall be available for building or construction of temporary 


pamtmann on DSKBC07HB2PROD with BILLS
13 

•HR 1371 IH

1 structures, leasing of properties, medical supplies and 

2 equipment including personal protective equipment and 

3 testing supplies, increased workforce and trainings, emer4 gency operation centers, retrofitting facilities, and surge 

5 capacity. 

6 (h) In this section, the term ‘‘payment’’ means a pre7 payment, prospective payment, or retrospective payment, 

8 as determined appropriate by the Secretary. 

9 (i) Payments under this section shall be made in con10 sideration of the most efficient payment systems prac11 ticable to provide emergency payment. 

12 (j) To be eligible for a payment under this section, 

13 an eligible health care provider shall submit to the Sec14 retary of Health and Human Services an application that 

15 includes a statement justifying the need of the provider 

16 for the payment and the eligible health care provider shall 

17 have a valid tax identification number. 

18 (k) Not later than 3 years after final payments are 

19 made under this section, the Office of Inspector General 

20 of the Department of Health and Human Services shall 

21 transmit a final report on audit findings with respect to 

22 this program to the Committees on Appropriations of the 

23 House of Representatives and the Senate. 


pamtmann on DSKBC07HB2PROD with BILLS
14 

•HR 1371 IH

1 (l) Nothing in this section limits the authority of the 

2 Inspector General or the Comptroller General to conduct 

3 audits of interim payments at an earlier date. 

4 (m) Not later than 60 days after the date of enact5 ment of this Act, the Secretary of Health and Human 

6 Services shall provide a report to the Committees on Ap7 propriations of the House of Representatives and the Sen8 ate on obligation of funds, including obligations to such 

9 eligible health care providers summarized by State of the 

10 payment receipt. 

11 (n) Such reports shall be updated and submitted to 

12 such Committees every 60 days until funds are expended. 

13 SEC. 10. FUNDING FOR BLOCK GRANTS FOR COMMUNITY 

14 MENTAL HEALTH SERVICES. 

15 In addition to amounts otherwise available, there is 

16 appropriated to the Secretary for fiscal year 2021, out of 

17 any money in the Treasury not otherwise appropriated, 

18 $1,750,000,000, to remain available until expended, for 

19 carrying out subpart I of part B of title XIX of the Public 

20 Health Service Act (42 U.S.C. 300x et seq.), subpart III 

21 of part B of title XIX of such Act (42 U.S.C. 300x–51 

22 et seq.), and section 505(c) of such Act (42 U.S.C. 290aa– 

23 4(c)) with respect to mental health. Notwithstanding sec24 tion 1952 of the Public Health Service Act (42 U.S.C. 

25 300x–62), any amount awarded to a State out of amounts 


pamtmann on DSKBC07HB2PROD with BILLS
15 

•HR 1371 IH

1 appropriated by this section shall be expended by the State 

2 by September 30, 2025. 

3 SEC. 11. FUNDING FOR BLOCK GRANTS FOR PREVENTION 

4 AND TREATMENT OF SUBSTANCE ABUSE. 

5 In addition to amounts otherwise available, there is 

6 appropriated to the Secretary for fiscal year 2021, out of 

7 any money in the Treasury not otherwise appropriated, 

8 $1,750,000,000, to remain available until expended, for 

9 carrying out subpart II of part B of title XIX of the Public 

10 Health Service Act (42 U.S.C. 300x–21 et seq.), subpart 

11 III of part B of title XIX of such Act (42 U.S.C. 300x– 

12 51 et seq.), section 505(d) of such Act (42 U.S.C. 290aa– 

13 4(d)) with respect to substance abuse, and section 515(d) 

14 of such Act (42 U.S.C. 290bb–21(d)). Notwithstanding 

15 section 1952 of the Public Health Service Act (42 U.S.C. 

16 300x–62), any amount awarded to a State out of amounts 

17 appropriated by this section shall be expended by the State 

18 by September 30, 2025. 

19 SEC. 12. MISCELLANEOUS PROVISIONS. 

20 (a) APPLICABLE REQUIREMENTS.—Amounts appro21 priated by this Act are subject to the requirements con22 tained in Public Law 116–94 for funds for programs au23 thorized under sections 330 through 340 of the Public 

24 Health Service Act (42 U.S.C. 254b et seq.). 


pamtmann on DSKBC07HB2PROD with BILLS
16 

•HR 1371 IH

1 (b) EMERGENCY DESIGNATION.—Amounts appro2 priated by this Act are designated by the Congress as 

3 being for an emergency requirement pursuant to section 

4 251(b)(2)(A)(i) of the Balanced Budget and Emergency 

5 Deficit Control Act of 1985. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS